Barclays analyst Andrew Mok raised the firm’s price target on Tenet Healthcare (THC) to $240 from $229 and keeps an Overweight rating on the shares. The firm says employer-sponsored insurance coverage looks under pressure but will be “potentially masked” by positive Affordable Care Act trends benefiting hospitals.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC: